ALK expects to have approved peanut allergy vaccine in 2030

After revealing that it is starting a phase I trial of its peanut allergy vaccine candidate, ALK has now announced that it expects to have an approved vaccine in 2030 at the latest.
Head of Research and Development at ALK, Henrik Jacobi
Head of Research and Development at ALK, Henrik Jacobi
by marketwire, translated by catherine brett

Head of R&D at ALK Henrik Jacobi thinks the decision to move into peanut allergies makes sense, as the firm already has a lot of experience of developing tablet-based vaccines.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
!
!
Must contain at least 6 characters
!
Must contain at least 2 characters
!
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

!
Newsletter terms

Front page now

Further reading